The Recall Desk

Hazard

Allergen Exposure recalls

168 recalls in our database tag this hazard, drawn from FDA, USDA FSIS, CPSC, and NHTSA source notices.

What the numbers show

Total
168
Critical
0
Severe
148
Most recent
2016-07-27

Of the 168 allergen exposure recalls we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 148 (88%) are Severe.

About this hazard tag

Hazard tags are short, machine-readable labels we attach to every recall to make cross-cutting queries possible — “all allergen exposure recalls regardless of agency”, “all listeria recalls in California”, “all airbag recalls in 2025”. The tags are extracted from each recall’s source text during the LLM rewrite step and validated against a fixed schema.

A recall can carry multiple tags — a Listeria recall might also be tagged ready-to-eat and undeclared-allergen. Use the full-text search if you want to combine hazard tags with brand or category filters.

26–50 of 168

  • SevereFDA (Drugs)·D-774-2015·2015-04-29

    Attix Pharmaceuticals Recalls Meclofenoxate HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Meclofenoxate HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Meclofenoxate HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-955-2015·2015-04-29

    Attix Pharmaceuticals Recalls Voriconazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Voriconazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Voriconazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-756-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levocetirizine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levocetirizine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Levocetirizine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-640-2015·2015-04-29

    Attix Pharmaceuticals Recalls Doxorubicin HCI Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Doxorubicin HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Doxorubicin HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-708-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hyaluronic Acid Sodium Salt Injection Grade API

    Attix Pharmaceuticals is recalling Hyaluronic Acid Sodium Salt (Injection Grade) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Hyaluronic Acid Sodium Salt (Injection Grade) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-668-2015·2015-04-29

    Attix Pharmaceuticals Recalls Everolimus API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of everolimus active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Everolimus active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-641-2015·2015-04-29

    Attix Pharmaceuticals Recalls Doxycycline HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Doxycycline HCI active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Doxycycline HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-814-2015·2015-04-29

    Attix Pharmaceuticals Recalls Natamycin API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Natamycin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The recall affects lots distributed nationwide to compounding pharmacies and research organizations.

    Product
    Natamycin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-789-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methyl 5-Aminolevulinate Hydrochloride Due to Penicillin Contamination Risk

    Attix Pharmaceuticals is recalling Methyl 5-Aminolevulinate Hydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Methyl 5-Aminolevulinate Hydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-569-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cefpodoxime Proxetil Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cefpodoxime Proxetil active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Cefpodoxime Proxetil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-680-2015·2015-04-29

    Flumethasone API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Flumethasone active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Flumethasone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-539-2015·2015-04-29

    Attix Pharmaceuticals Recalls Benztropine Mesylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Benztropine Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Benztropine Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-946-2015·2015-04-29

    Attix Pharmaceuticals Recalls Uridine-5'Triphosphate Trisodium Salt Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Uridine-5'Triphosphate Trisodium Salt active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Uridine-5'Triphosphate Trisodium Salt active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-853-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pralidoxime Chloride Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Pralidoxime Chloride active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Pralidoxime Chloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-719-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydroxocobalamin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydroxocobalamin Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hydroxocobalamin Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-825-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ondansetron HCl Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ondansetron HCl Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ondansetron HCl Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-702-2015·2015-04-29

    Halobetasol Propionate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Halobetasol Propionate active ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Halobetasol Propionate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-663-2015·2015-04-29

    Attix Pharmaceuticals Recalls Etidronate Disodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Etidronate Disodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Etidronate Disodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-717-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydroxocobalamin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydroxocobalamin active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Hydroxocobalamin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-622-2015·2015-04-29

    Attix Pharmaceuticals Recalls Desoximetasone Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Desoximetasone active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Desoximetasone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-840-2015·2015-04-29

    Attix Pharmaceuticals Recalls Phenoxybenzamine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Phenoxybenzamine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Phenoxybenzamine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-635-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dobutamine Hydrochloride Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dobutamine Hydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Dobutamine Hydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-562-2015·2015-04-29

    Attix Pharmaceuticals Recalls Carboplatin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Carboplatin active pharmaceutical ingredient repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Carboplatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-612-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dantrolene Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dantrolene Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dantrolene Sodium (Orange) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-491-2015·2015-04-29

    Attix Pharmaceuticals Recalls 5-Aminolevulinic Acid Hydrochloride Due to Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling 5-Aminolevulinic Acid Hydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    5-Aminolevulinic Acid Hydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide